AK112/Olaparib Combo Under Exploration in BRCA1/2 Wild-Type, Recurrent Ovarian Cancer
November 17th 2021The combination of the PD-1/VEGF bispecific antibody AK112 and the PARP inhibitor olaparib is under investigation as a potential treatment option for patients with BRCA1/2 germline wild-type, platinum-sensitive, recurrent ovarian cancer as part of a phase 1b/2 trial.
SL-172154 Shows Favorable Tolerability in Platinum-Resistant Ovarian Cancer
November 17th 2021The investigative agent SL-172154 was found to be well tolerated, with no dose-limiting toxicities observed, in patients with platinum-resistant ovarian cancer, according to findings from a phase 1 dose-escalation trial presented during the 2021 SITC Annual Meeting.
Investigators Aim to Identify New Treatment Targets with Cancer Cell Map Initiative
November 16th 2021The Cancer Cell Map Initiative, developed by investigators at the University of California San Francisco and the University of California San Diego, has successfully charted how hundreds of genetic mutations involved in breast cancer and cancers of the head and neck affect the activity of proteins that ultimately lead to disease.
First-in-class Anti-CD47 Fusion Protein DSP107 Under Investigation in AML and MDS
November 10th 2021The FDA cleared an investigational new drug application for a phase 1b clinical trial examining DSP107, a first-in-class anti-CD47 fusion protein, in patients with acute myeloid leukemia and myelodysplastic syndrome.
FDA Clears IND to Expand ABILITY Trial Examining MDNA11 in Solid Tumors to the United States
November 9th 2021The FDA has greenlit an investigation new drug application to expand the ongoing phase 1/2 ABILITY trial, which is evaluating the beta-only IL-2 superagonist MDNA11 in patients with solid tumors, to clinical trial sites in the United States.